The Argonne National Laboratory announced yesterday the successful validation of a key component of SHINE Medical’s molybdenum-99 production process. Argonne successfully demonstrated the production, separation and purification of Mo-99 from SHINE’s liquid target, known as Mini-SHINE, which will be used in the company’s production process, further validating SHINE’s process. “This key demonstration proves that SHINE’s innovative target and processing chemistry produces Mo-99 that has the same purity as what customers are purchasing today,” SHINE CEO Greg Piefer said in a statement. “It is essentially a pilot demonstration of one of the two novel parts of our plant. Argonne has worked tirelessly to provide this demonstration, which otherwise would not be available until after the plant is operational.” According to the company, the demonstration proves that the chemistry of the liquid target holds up through every part of the process.
Jobs